DENTSPLY SIRONA (NASDAQ:XRAY) Shares Down 8.4% – What’s Next?

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) shares traded down 8.4% on Friday . The company traded as low as $12.08 and last traded at $12.0640. 1,294,629 shares were traded during trading, a decline of 74% from the average daily volume of 5,021,003 shares. The stock had previously closed at $13.17.

Analysts Set New Price Targets

XRAY has been the topic of several research reports. Barclays cut their target price on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Thursday, June 4th. Citigroup began coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target on the stock. Piper Sandler increased their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. UBS Group reduced their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a report on Friday. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, DENTSPLY SIRONA currently has an average rating of “Hold” and a consensus price target of $13.54.

DENTSPLY SIRONA Stock Performance

The firm’s 50 day moving average is $11.74 and its 200-day moving average is $11.89. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of -3.87, a PEG ratio of 1.64 and a beta of 0.85. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. During the same quarter last year, the business earned $0.52 earnings per share. The firm’s revenue was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts forecast that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael J. Barber acquired 15,175 shares of DENTSPLY SIRONA stock in a transaction on Thursday, June 11th. The stock was bought at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the transaction, the director owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. The trade was a 37.22% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Brian P. Mckeon acquired 10,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were bought at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at approximately $101,200. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 35,160 shares of company stock valued at $351,179. 0.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several institutional investors have recently bought and sold shares of XRAY. First Eagle Investment Management LLC increased its stake in DENTSPLY SIRONA by 3.2% during the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after buying an additional 458,744 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after acquiring an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC lifted its position in shares of DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after acquiring an additional 92,868 shares in the last quarter. Southpoint Capital Advisors LP acquired a new stake in shares of DENTSPLY SIRONA in the first quarter worth approximately $116,000,000. Finally, Armistice Capital LLC boosted its stake in shares of DENTSPLY SIRONA by 27.2% in the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock worth $83,416,000 after acquiring an additional 1,562,000 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.